All Signals
Company Overview
About
A specialty ophthalmic pharmaceutical company developing the EPIPLANT™ episcleral implant platform for sustained drug delivery to retinal tissues.
Founders / Leaders
Karl CsakyPhilip A. Gioia
Industry
BioTech
Location
Avon-by-the-Sea, United States
Hiring
Not hiring
Latest Funding Signal
$8M
Series AOctober 8, 2026
Vinci Pharmaceuticals Raises $8M+ Series A to Advance Sustained Retinal Drug Delivery Platform
Lead Investors
Dynagrow Capital, LLLP
Other Investors
MintPharma Capital
Use of Funds
Proceeds are expected to support GMP manufacturing, testing and release activities for the EPIPLANT™ VCI-002 product and the Phase 1/2a study planned for 2027.